{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+formulation&page=2",
    "query": {
      "intervention": "control formulation",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+formulation&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T05:44:56.790Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01658579",
      "title": "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "HOE901-U300 (new formulation of insulin glargine)",
          "type": "DRUG"
        },
        {
          "name": "Lantus (insulin glargine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 59,
      "start_date": "2012-08",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2015-06-01",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 3,
      "location_summary": "Temecula, California • Minneapolis, Minnesota • Portland, Oregon",
      "locations": [
        {
          "city": "Temecula",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658579"
    },
    {
      "nct_id": "NCT04362670",
      "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OTX-CSI",
          "type": "DRUG"
        },
        {
          "name": "Placebo Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2020-04-23",
      "completion_date": "2021-08-11",
      "has_results": true,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 15,
      "location_summary": "Garden Grove, California • Inglewood, California • Mission Hills, California + 11 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04362670"
    },
    {
      "nct_id": "NCT07220694",
      "title": "Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insulin Resistance",
        "Mild Cognitive Impairment",
        "Cognitive Decline",
        "Neurodegenerative Disorders"
      ],
      "interventions": [
        {
          "name": "Sabroxy®",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "SF Research Institute, Inc.",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 140,
      "start_date": "2026-01-29",
      "completion_date": "2026-04-29",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220694"
    },
    {
      "nct_id": "NCT04419025",
      "title": "Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID",
        "Sars-CoV2",
        "SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere",
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cambridge Health Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2020-09-23",
      "completion_date": "2021-05-14",
      "has_results": false,
      "last_update_posted_date": "2021-05-28",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 4,
      "location_summary": "Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "Everett",
          "state": "Massachusetts"
        },
        {
          "city": "Somerville",
          "state": "Massachusetts"
        },
        {
          "city": "Somerville",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04419025"
    },
    {
      "nct_id": "NCT01877421",
      "title": "Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Plaque",
        "Gingivitis"
      ],
      "interventions": [
        {
          "name": "2 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "4 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "6 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "10 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "20 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "30 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "50 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "75 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "100 mg KSL-W",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 135,
      "start_date": "2014-02-25",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2020-02-13",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01877421"
    },
    {
      "nct_id": "NCT02994992",
      "title": "Sun Protection Factor Assay (316/2016)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sunscreening Agents"
      ],
      "interventions": [
        {
          "name": "BAY 987516",
          "type": "DRUG"
        },
        {
          "name": "SPF Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-12-22",
      "completion_date": "2017-01-13",
      "has_results": false,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 1,
      "location_summary": "Union, New Jersey",
      "locations": [
        {
          "city": "Union",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02994992"
    },
    {
      "nct_id": "NCT04933799",
      "title": "IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "PF-06650833",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Giovanni Franchin, M.D, Ph.D",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2021-01-06",
      "completion_date": "2022-05-06",
      "has_results": false,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04933799"
    },
    {
      "nct_id": "NCT01113034",
      "title": "A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Bronchiectasis"
      ],
      "interventions": [
        {
          "name": "DAS181 dry powder, formulation F02",
          "type": "DRUG"
        },
        {
          "name": "Respitose ML006 (DMV-Fonterra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ansun Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 11,
      "start_date": "2010-07",
      "completion_date": "2011-08-22",
      "has_results": false,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01113034"
    },
    {
      "nct_id": "NCT02120898",
      "title": "A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Imiquimod",
          "type": "DRUG"
        },
        {
          "name": "Zyclara®",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 467,
      "start_date": "2013-10-10",
      "completion_date": "2014-04-30",
      "has_results": true,
      "last_update_posted_date": "2019-12-13",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02120898"
    },
    {
      "nct_id": "NCT04280705",
      "title": "Adaptive COVID-19 Treatment Trial (ACTT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 1062,
      "start_date": "2020-02-21",
      "completion_date": "2020-05-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-09-04T05:44:56.790Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04280705"
    }
  ]
}